These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
274 related articles for article (PubMed ID: 3556779)
21. Response to early measles-mumps-rubella vaccination in infants with chronic renal failure and/or receiving peritoneal dialysis. Flynn JT; Frisch K; Kershaw DB; Sedman AB; Bunchman TE Adv Perit Dial; 1999; 15():269-72. PubMed ID: 10682116 [TBL] [Abstract][Full Text] [Related]
22. Measles immunity in HIV-infected children. Walter EB; Katz SL; Bellini WJ Pediatr AIDS HIV Infect; 1994 Oct; 5(5):300-4. PubMed ID: 11361371 [TBL] [Abstract][Full Text] [Related]
23. Serological evaluation of a measles, mumps, and rubella vaccine. Robertson CM; Bennett VJ; Jefferson N; Mayon-White RT Arch Dis Child; 1988 Jun; 63(6):612-6. PubMed ID: 3291787 [TBL] [Abstract][Full Text] [Related]
24. Antibody response to measles-mumps-rubella vaccine of children with mild illness at the time of vaccination. Should we be concerned? Watada B; Kennedy K; Chan D; Church B; Patriquin M; Shariff F; Evans MF Can Fam Physician; 1998 Jan; 44():53-5. PubMed ID: 9481462 [No Abstract] [Full Text] [Related]
26. [Measles, mumps and rubella: vaccination rate and seroprevalence in 8th grade students of 8 different sites in Switzerland 1995/96]. Stohrer-Draxl P; Amstad H; Grize L; Gassner M; Takken-Sahli K; Bourquin C; Braun-Fahrländer C Praxis (Bern 1994); 1999 Jun; 88(24):1069-77. PubMed ID: 10420798 [TBL] [Abstract][Full Text] [Related]
27. [Morbidity, vaccine coverage and immunity against measles, mumps and rubella in a Gallician population from 2 to 5 years old]. Vázquez Fernández E; López Rois F; Vázquez Carrete JA; Gómez Tato B; Alvarez Ares M An Esp Pediatr; 1987 Jul; 27(1):27-31. PubMed ID: 3662251 [TBL] [Abstract][Full Text] [Related]
28. Gender differences in the reactogenicity of measles-mumps-rubella vaccine. Shohat T; Green MS; Nakar O; Ballin A; Duvdevani P; Cohen A; Shohat M Isr Med Assoc J; 2000 Mar; 2(3):192-5. PubMed ID: 10774264 [TBL] [Abstract][Full Text] [Related]
29. Vaccine-induced measles virus antibodies after two doses of combined measles, mumps and rubella vaccine: a 12-year follow-up in two cohorts. Davidkin I; Valle M Vaccine; 1998 Dec; 16(20):2052-7. PubMed ID: 9796064 [TBL] [Abstract][Full Text] [Related]
30. Correlates of lymphoproliferative responses to measles, mumps, and rubella (MMR) virus vaccines following MMR-II vaccination in healthy children. Dhiman N; Ovsyannikova IG; Jacobson RM; Vierkant RA; Pankratz VS; Jacobsen SJ; Poland GA Clin Immunol; 2005 May; 115(2):154-61. PubMed ID: 15885638 [TBL] [Abstract][Full Text] [Related]
31. Serosurvey of measles, mumps and rubella antibodies in Saudi children. Al-Mazrou YY; Khalil MK; Tischer A; Al-Jeffri MH; Al-Ghamdi YS; Bakhsh MM; Mishkas AA; Elgizouli SA Saudi Med J; 2005 Oct; 26(10):1551-4. PubMed ID: 16228054 [TBL] [Abstract][Full Text] [Related]
32. [The clinico-immunological evaluation of a bivalent vaccine against measles and rubella]. Schettini F; Manzionna MM; De Mattia D; Amendola F; Di Bitonto G Minerva Pediatr; 1990 Dec; 42(12):531-6. PubMed ID: 2087226 [TBL] [Abstract][Full Text] [Related]
33. [Immune status against measles and rubella among 4 Chilean groups of different ages]. Valenzuela MT; Vega J; Leal I; Vicente M; Young V; Vera L; Fasce R; Ramírez E Rev Med Chil; 1999 Mar; 127(3):359-65. PubMed ID: 10436723 [TBL] [Abstract][Full Text] [Related]
34. Seroepidemiological study of measles after the 1992 nationwide MMR revaccination program in Taiwan. Chiu HH; Lee CY; Chih TW; Lee PI; Chang LY; Lin YJ; Hsu CM; Huang LM J Med Virol; 1997 Jan; 51(1):32-5. PubMed ID: 8986946 [TBL] [Abstract][Full Text] [Related]
35. Vaccination against measles, mumps and rubella (MMR): a comparison between the antibody responses at the ages of 18 months and 12 years and between different methods of antibody titration. Christenson B; Böttiger M J Biol Stand; 1985 Apr; 13(2):167-72. PubMed ID: 3997899 [TBL] [Abstract][Full Text] [Related]
36. [Field trial with a new human diploid cell vaccine (HDCV) against measles, mumps and rubella]. Just M; Berger R; Glück R; Wegmann A Schweiz Med Wochenschr; 1985 Nov; 115(48):1727-30. PubMed ID: 4081704 [TBL] [Abstract][Full Text] [Related]
37. Prevalence of IgG antibody against measles, mumps and rubella in bangladeshi children: a pilot study to evaluate the need for integrated vaccination strategy. Sultana R; Rahman MM; Hassan Z; Hassan MS Scand J Immunol; 2006 Dec; 64(6):684-9. PubMed ID: 17083626 [TBL] [Abstract][Full Text] [Related]
38. Aerosolized measles and measles-rubella vaccines induce better measles antibody booster responses than injected vaccines: randomized trials in Mexican schoolchildren. Bennett JV; Fernandez de Castro J; Valdespino-Gomez JL; Garcia-Garcia Mde L; Islas-Romero R; Echaniz-Aviles G; Jimenez-Corona A; Sepulveda-Amor J Bull World Health Organ; 2002; 80(10):806-12. PubMed ID: 12471401 [TBL] [Abstract][Full Text] [Related]
39. Clinical and serologic evaluation of measles, mumps, and rubella (HPV-77:DE-5 and RA 27/3) virus vaccines, singly and in combination. Lerman SJ; Bollinger M; Brunken JM Pediatrics; 1981 Jul; 68(1):18-22. PubMed ID: 7017582 [TBL] [Abstract][Full Text] [Related]